Condition: Peripheral Vascular Disease · Peripheral Arterial Disease · Sponsor: Cook Research Incorporated
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
This description comes directly from the study's public registry record.
Noah Shields · 765-463-7537 · noah.shields@cookmedical.com
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| The Cardiac and Vascular Institute | Gainesville, Florida, United States | Recruiting |
| First Coast Cardiovascular Institute | Jacksonville, Florida, United States | Recruiting |
| Baptist Cardiac and Vascular Institute | Miami, Florida, United States | Recruiting |
| Midwest Cardiovascular Research Foundation | Davenport, Iowa, United States | Recruiting |
| North Mississippi Medical Center | Tupelo, Mississippi, United States | Recruiting |
| Prisma Health Memorial | Greenville, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07144150